Oculis Holding AG (OCS)

NASDAQ: OCS · IEX Real-Time Price · USD
-0.27 (-3.31%)
Mar 20, 2023, 4:00 PM EDT - Market closed
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,821
Open 8.55
Previous Close 8.02
Day's Range 7.50 - 8.55
52-Week Range 7.50 - 13.95
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About OCS

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 32
Stock Exchange NASDAQ
Ticker Symbol OCS
Full Company Profile


Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

LAUSANNE, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today an...

4 days ago - GlobeNewsWire

Oculis Announces US Public Listing on NASDAQ

Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq-listed ophthalmology company, under the ticker “OCS”, with advanced clinical-stage pipeline of multiple product c...

2 weeks ago - GlobeNewsWire

European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report

NEW YORK--(BUSINESS WIRE)--European Biotech Acquisition Corp. receives expected notification from Nasdaq related to delayed quarterly report.

1 year ago - Business Wire